Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandre André

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Pathology, Research and Practice|December 20, 2017
Prognostic value of GRIM-19, NF-κB and IKK2 in patients with high-grade serous ovarian cancerFelipe Ilelis, Nayra Soares do Amaral, Mariana Rezende Alves, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 15, 2024
PARG inhibitor sensitivity correlates with accumulation of single-stranded DNA gaps in preclinical models of ovarian cancerRamya Ravindranathan, Ozge Somuncu, Alexandre André B A da Costa, et al.
Annals of Surgical Oncology|November 22, 2020
Impact of BRCA1/2 Mutations on the Efficacy of Secondary Cytoreductive SurgeryFelipe Leonardo Estati, Rafaela Pirolli, Viviane Teixeira Loiola de Alencar, et al.
Oncology Reports|February 6, 2019
Prostaglandin D2 expression is prognostic in high‑grade serous ovarian cancerMariana Rezende Alves, Nayra Soares Do Amaral, Fabio Albuquerque Marchi, et al.
Current Oncology (Toronto, Ont.)|February 24, 2022
Case Report of Small Cell Carcinoma of the Ovary, Hypercalcemic Type (Ovarian Rhabdoid Tumor) with <i>SMARCB1</i> Mutation: A Literature Review of a Rare and Aggressive ConditionMaria Fernanda Evangelista Simões, Alexandre André Balieiro Anastácio da Costa, Tullio Novaes Silva, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|February 17, 2019
Risk factors for pelvic and distant recurrence in locally advanced cervical cancerAna Carolina Matos Queiroz, Vanessa Fabri, Henrique Mantoan, et al.
BMC Cancer|September 24, 2015
Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survivalTadeu Ferreira Paiva, Victor Hugo Fonseca de Jesus, Raul Amorim Marques, et al.
BMC Cancer|May 9, 2021
Comparison of dose-dense vs. 3-weekly paclitaxel and carboplatin in the first-line treatment of ovarian cancer in a propensity score-matched cohortRafaela Pirolli, Viviane Teixeira Loiola de Alencar, Felipe Leonardo Estati, et al.
BMC Cancer|July 3, 2023
Genomic landscapes of ovarian clear cell carcinoma from latin countries reveal aberrations linked to survival and progressionMariana de Paiva Batista, Martín Roffé, Ignacio Romero, et al.
Cancer Genetics|November 29, 2019
MIR605 rs2043556 is associated with the occurrence of multiple primary tumors in TP53 p.(Arg337His) mutation carriersIsabel Cristina Bandeira, Igor Araujo Vieira, Tiago Finger Andreis, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Pathology, Research and Practice|December 20, 2017
Prognostic value of GRIM-19, NF-κB and IKK2 in patients with high-grade serous ovarian cancerFelipe Ilelis, Nayra Soares do Amaral, Mariana Rezende Alves, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 15, 2024
PARG inhibitor sensitivity correlates with accumulation of single-stranded DNA gaps in preclinical models of ovarian cancerRamya Ravindranathan, Ozge Somuncu, Alexandre André B A da Costa, et al.
Annals of Surgical Oncology|November 22, 2020
Impact of BRCA1/2 Mutations on the Efficacy of Secondary Cytoreductive SurgeryFelipe Leonardo Estati, Rafaela Pirolli, Viviane Teixeira Loiola de Alencar, et al.
Oncology Reports|February 6, 2019
Prostaglandin D2 expression is prognostic in high‑grade serous ovarian cancerMariana Rezende Alves, Nayra Soares Do Amaral, Fabio Albuquerque Marchi, et al.
Current Oncology (Toronto, Ont.)|February 24, 2022
Case Report of Small Cell Carcinoma of the Ovary, Hypercalcemic Type (Ovarian Rhabdoid Tumor) with <i>SMARCB1</i> Mutation: A Literature Review of a Rare and Aggressive ConditionMaria Fernanda Evangelista Simões, Alexandre André Balieiro Anastácio da Costa, Tullio Novaes Silva, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|February 17, 2019
Risk factors for pelvic and distant recurrence in locally advanced cervical cancerAna Carolina Matos Queiroz, Vanessa Fabri, Henrique Mantoan, et al.
BMC Cancer|September 24, 2015
Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survivalTadeu Ferreira Paiva, Victor Hugo Fonseca de Jesus, Raul Amorim Marques, et al.
BMC Cancer|May 9, 2021
Comparison of dose-dense vs. 3-weekly paclitaxel and carboplatin in the first-line treatment of ovarian cancer in a propensity score-matched cohortRafaela Pirolli, Viviane Teixeira Loiola de Alencar, Felipe Leonardo Estati, et al.
BMC Cancer|July 3, 2023
Genomic landscapes of ovarian clear cell carcinoma from latin countries reveal aberrations linked to survival and progressionMariana de Paiva Batista, Martín Roffé, Ignacio Romero, et al.
Cancer Genetics|November 29, 2019
MIR605 rs2043556 is associated with the occurrence of multiple primary tumors in TP53 p.(Arg337His) mutation carriersIsabel Cristina Bandeira, Igor Araujo Vieira, Tiago Finger Andreis, et al.
Pageof 3